ALK CEO: We call the FDA on a daily basis

Denmark’s ALK is ready to go “full steam” in the launch of a promising tablet against house dust mite allergy on the US market as early as this year. The only obstacle is a formal handover of the marketing permit from former partner Merck, which could push the launch into 2018.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

Lægemiddelstyrelsen er skuffet, men glad for bronzen

Lægemiddelstyrelsens direktør Thomas Senderovitz er skuffet over, at København ikke skal huse EMA, men også stolt over at have snuppet "bronzemedaljerne". Han påpeger dog også, at der ligger masser af arbejde forude i forbindelse med flytningen af lægemiddelagenturet.

Latest Top picks in English

Related articles